(CNN) — The Food and Drug Administration will authorize Pfizer’s new clavulanate heart drug for all adults before the week’s end, according to reports by the Wall Street Journal and Reuters, citing unnamed people familiar with the matter.
Pfizer is already selling the drug in four “medically indicated doses” ranging from 40 mg to 200 mg in adults ages 18 to 65 with heart issues.
Clavulanate “is used to increase blood flow to the heart, replacing or improving blood flow to the heart muscle,” according to Pfizer’s product description.
The drug’s FDA approval also includes a warning that patients may experience “pain and swelling of the fingers and toes.” That is usually associated with glaucoma or a deep vein thrombosis, according to the drug’s label.
Clavulanate, a beta blocker, has been approved for reducing blood pressure.
Clavulanate has already been approved for treating high blood pressure in adults with coronary artery disease in the United States, as well as patients with uncontrolled high blood pressure and other medical conditions.
A Pfizer spokeswoman would not confirm or deny the plans to sell the drug to all adults. She sent CNN a statement:
“We cannot discuss confidential conversations between our partners and the FDA,” the spokeswoman said. “We are committed to providing therapies that improve patients’ lives, and we will continue to work with the FDA to provide our patients with the latest understanding and treatment options for heart disease.”
GlaxoSmithKline also sells a beta blocker called nimodipine extended-release tablets.